Northwest Behavioral Research Center

Schizophrenia/Schizoaffective Disorder Studies

Current Clinical Research Studies (as of November 1, 2011)
Contact jennifer@nbmedicine.com for more details

Marietta Office-770-422-2846

Schizoaffective Disorder Long Term Study:

This is a study studying the response and relapse prevention of the long acting injection Invega Sustenna (a currently approved medication for schizoaffective disorder).

Participants receive the Invega Sustenna for 13 weeks to find the appropriate dose, another 12 weeks to insure they remain stable on that dose, and then are randomized to stay on the injection or to placebo.

They may stay on either an antidepressants or mood stabilizer throughout the study (but not both).

Criteria:

Adult Schizophrenia Study-Add on Medication Study to Current Antipsychotic

This is a study for those with ongoing negative symptoms or still symptomatic on current antipsychotic.

They stay on their antipsychotic and are randomized to receive a novel medication being studied to see if their symptoms improve or to a placebo.

They must have someone who is caretaker that can come with them to appointments.

Adult Schizophrenia Study Using a Once-a Month Abilify Injection

If you have been hospitalized at least once in the last 2 years and have a diagnosis of

Schizophrenia, you may qualify for this study.

You will receive an open -label Abilify Injection every month. There is no placebo in this study.